Nucleic acids encoding interleukin-31 monoclonal antibody and uses thereof
View Patent ↗An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.
1. A host cell that produces an isolated antibody or antigen-binding portion thereof comprising at least one of the following combinations of complementary determining region (CDR) sequences:
1) 11E12: variable heavy (VH)-CDR1 of SEQ ID NO: 1, VH-CDR2 of SEQ ID NO: 4, VH-CDR3 of SEQ ID. NO: 7, variable light (VL)-CDR1 of SEQ ID NO: 10, VL-CDR2 of SEQ ID NO: 13, and VL-CDR3 of SEQ ID NO: 16;
2) 19D07: VH-CDR1 of SEQ ID NO: 2, VH-CDR2 of SEQ ID NO: 5, VH-CDR3 of SEQ ID NO: 8, VL-CDR1 of SEQ ID NO: 11, VL-CDR2 of SEQ ID NO: 14, and VL-CDR3 of SEQ ID NO 17; or
3) 34D03: VH-CDR1 of SEQ ID NO: 3, VH-CDR2 of SEQ ID NO: 6, VH-CDR3 of SEQ ID NO: 9, VL-CDR1 of SEQ ID NO: 12, VL-CDR2 of SEQ ID NO: 15, and VL-CDR3 of SEQ ID NO: 18.
2. The host cell of claim 1 , wherein said antibody reduces, inhibits, or neutralizes an IL-31-mediated pruritic or allergic condition in a dog or cat.
3. The host cell of claim 2 , wherein the IL-31-mediated pruritic or allergic condition is a pruritic condition selected from the group consisting of atopic dermatitis, eczema, psoriasis, scleroderma, and pruritis.
4. The host cell of claim 2 , wherein the IL-31-mediated pruritic or allergic condition is an allergic condition selected from the group consisting of allergic dermatitis, summer eczema, urticaria, heaves, inflammatory airway disease, recurrent airway obstruction, airway hyper-responsiveness, chronic obstruction pulmonary disease, and inflammatory processes resulting from autoimmunity.
5. A method of producing an antibody comprising culturing the host cell of claim 2 under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture medium of the host cell.
6. A method of producing an antibody comprising culturing the host cell of claim 1 under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture medium of the host cell.
7. An isolated nucleic acid comprising a nucleic acid sequence encoding at least one of the following combinations of complementary determining region (CDR) sequences:
1) 11 E12: variable heavy (VH)-CDR1 of SEQ ID NO. 1, VH-CDR2 of SEQ ID NO: 4, and VH-CDR3 of SEQ ID NO: 7;
2) 19D07: VH-CDR1 of SEQ ID NO: 2, VH-CDR2 of SEQ ID NO: 5, and VH-CDR3 of SEQ ID NO: 8; or
3) 34D03: VH-CDR1 of SEQ ID NO: 3, VH-CDR2 of SEQ ID NO:6, and VH-CDR3 of SEQ ID NO: 9.
8. The nucleic acid of claim 7 , further comprising a nucleic acid sequence encoding at least one of the following combinations of CDR sequences:
1) 11E12: variable light (VL)-CDR1 of SEQ ID NO: 10, VL-CDR2 of SEQ ID NO: 13, and VL-CDR3 of SEQ ID NO: 16;
2) 19D07: VL-CDR1 of SEQ ID NO: 11, VL-CDR2 of SEQ ID NO: 14, and VL-CDR3 of SEQ ID NO 17; or
3) 34D03: VL-CDR1 of SEQ ID NO: 12, VL-CDR2 of SEQ ID NO. 15, and VL-CDR3 of SEQ ID NO: 18.
9. A vector comprising the nucleic acid of claim 8 .
10. A vector comprising the nucleic acid of claim 7 .
11. An isolated nucleic acid comprising a nucleic acid sequence encoding at least one of the following combinations of complementary determining region (CDR) sequences:
1) 11E12: variable light (VL)-CDR1 of SEQ ID NO: 10, VL-CDR2 of SEQ ID NO: 13, and VL-CDR3 of SEQ ID NO: 16;
2) 19D07: VL-CDR1 of SEQ ID NO: 11, VL-CDR2 of SEQ ID NO: 14, and VL-CDR3 of SEQ ID NO 17; or
3) 34D03: VL-CDR1 of SEQ ID NO: 12, VL-CDR2 of SEQ ID NO 15, and VL-CDR3 of SEQ ID NO: 18.
12. A vector comprising the nucleic acid of claim 11 .